Breast Cancer Research and Treatment最新文献

{"title":"Association between Extract Rheum rhaponticum 731 (ERr 731) prescription and subsequent breast cancer.","authors":"Peter W Heger, Dirk Hotz, Matthias Kalder, Karel Kostev","doi":"10.1007/s10549-025-07711-9","DOIUrl":"10.1007/s10549-025-07711-9","url":null,"abstract":"<p><strong>Aims: </strong>The special extract ERr 731 from the roots of rhapontic rhubarb has been prescribed for women with menopausal symptoms for more than 30 years. The aim of the present study is to evaluate the association between ERr 731 therapy and subsequent breast cancer in women in a real-world setting. ERr 731 users were compared to women without this therapy as well as women receiving hormone therapy.</p><p><strong>Methods: </strong>This retrospective cohort study included data of women treated by 260 office-based gynecologists in Germany who received a prescription for ERr 731 between 1993 and 2022 (IQVIA Disease Analyzer database). These women were matched to women without ERr 731 prescriptions as well as women with hormone replacement therapy (HRT) prescriptions (1:3) using nearest neighbor propensity scores. A univariate Cox regression analysis was conducted to evaluate the associations between ERr 731 prescription and breast cancer risk compared to women without ERr 731 prescription and women with HRT prescriptions.</p><p><strong>Results: </strong>A total of 5,686 women with versus 17,058 women without ERr 731 prescription were available for the first analysis, and 2,616 women with ERr 731 prescription (a proportion of the 5,686 women used in the first analysis) and 7,848 women with HRT prescriptions for the second (average age 52-53 years). ERr 731 was not associated with an increased risk of breast cancer diagnosis when the group of women with ERr 731 prescription was compared to women without (OR: 1.01, 95% CI: 0.81-1.26) or to that of women with HRT prescription ((OR: 0.96, 95% CI: 0.69-1.33). No associations were observed in age-stratified analyses or in women with and without menopausal or other perimenopausal disorders.</p><p><strong>Conclusion: </strong>The present study provides strong evidence that ERr 731 is not associated with an increased risk of breast cancer diagnosis compared to both non-users and HRT users. Given its favorable safety profile, ERr 731 may represent a viable alternative to HRT, particularly for women concerned about breast cancer risk.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"139-148"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12086110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic skin toxicities in breast cancer survivors: a systematic review and meta-analysis of radiotherapy techniques.","authors":"Shing Fung Lee, Henry C Y Wong, Jolien Robijns, Stephen Lowell B Ciocon, Paula Elaine Diniz Dos Reis, Sarina Sadeghi, Muna Al-Khaifi, Mami Ogita, Adrian W Chan, Agata Rembielak, Daniel Livesey, Matthew Chong, Zhihui Amy Liu, Mark Trombetta, Wee Yao Koh, Yiat Horng Leong, Gustavo N Marta, Pierluigi Bonomo, Viola Salvestrini, Vassilios Vassiliou, Pradnya Chopade, Partha Patel, Cindy Wong, Julie Ryan Wolf, Corina van den Hurk, Raymond J Chan, Michael Jefford, Edward Chow, Jennifer Yin Yee Kwan","doi":"10.1007/s10549-025-07700-y","DOIUrl":"10.1007/s10549-025-07700-y","url":null,"abstract":"<p><strong>Purpose: </strong>This study assessed the impact of radiotherapy (RT) techniques on chronic skin reactions and health-related quality of life (HRQoL) in breast cancer patients, comparing conventional RT with modern techniques such as intensity-modulated RT (IMRT).</p><p><strong>Methods: </strong>A comprehensive search was conducted in Embase, MEDLINE, and Cochrane CENTRAL from inception to April 26, 2024. Conventional RT, which uses 2D or 3D imaging to shape radiation beams without dynamic intensity modulation, was compared with alternate RT techniques for adjuvant breast cancer treatment. Primary outcomes included chronic grade ≥ 2 skin toxicities (hyperpigmentation, breast fibrosis, telangiectasia, edema, and atrophy/retraction) and HRQoL, assessed mainly with EORTC QLQ-C30 and QLQ-BR23 modules. Pooled risk ratios (RR) with 95% confidence intervals (CI) were calculated using a random-effects model.</p><p><strong>Results: </strong>From 1305 screened studies, nine articles representing seven studies (2418 patients), including three randomized controlled trials, met inclusion criteria. Most studies used conventional fractionation (45-50 Gray in 25 fractions). IMRT was associated with a lower incidence of chronic grade ≥ 2 hyperpigmentation (RR: 0.39, 95%CI: 0.17-0.89, I² = 0%) compared to conventional RT. No significant differences were found for grade ≥ 2 breast fibrosis, telangiectasia, edema, and atrophy/retraction. Cosmetic outcomes from IMRT were favorable in the short term, with no long-term differences. Three studies reported no significant HRQoL differences between IMRT and conventional RT.</p><p><strong>Conclusion: </strong>IMRT may reduce certain chronic skin toxicities compared to conventional RT. However, consistent long-term differences in cosmetic outcomes or HRQoL were not observed. These findings are limited by the small number of studies and variability in reporting standards.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"1-12"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Our response to the letter to the editor for the article \"Comparison of survival between unilateral and bilateral breast cancers using propensity score matching: a retrospective single-center analysis\".","authors":"Ruşen Coşar, Necdet Süt","doi":"10.1007/s10549-025-07688-5","DOIUrl":"10.1007/s10549-025-07688-5","url":null,"abstract":"<p><p>They expressed their concerns about making comments regarding the sample size in our study. The preferred propensity score analysis was the statistical method chosen because it is the analysis after balancing the small number of patients with the much larger number of patients in this situation in terms of both number and prognostic factors. In fact, the reference to future studies on this subject has been made for new retrospective series rather than prospective randomized studies. We wanted to draw the attention of researchers to propensity score analysis and to show that future retrospective series studies can ask questions with clearer answers using propensity score analysis.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"185-186"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143953537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of pembrolizumab on ovarian function in young triple-negative breast cancer patients treated with chemo-immunotherapy.","authors":"Anne Perdrix, Nathalie Olympios, Jean Rouvet, Marie Degremont, Camille Fontaine, Baptiste Boitel, Roman Vion, Marianne Leheurteur, Florian Clatot","doi":"10.1007/s10549-025-07702-w","DOIUrl":"10.1007/s10549-025-07702-w","url":null,"abstract":"<p><strong>Purpose: </strong>Pembrolizumab plus neoadjuvant chemotherapy (P-CT) is the new standard in early-stage triple-negative breast cancers (TNBC). Pembrolizumab impact on ovarian reserve remained unknown. We evaluated the impact of pembrolizumab on ovarian reserve, through plasmatic Anti-Müllerian (AMH) analysis, in young TNBC patients.</p><p><strong>Methods: </strong>TNBC patients < 43 years treated by P-CT (carboplatin/paclitaxel/epirubicin/cyclophosphamide plus pembrolizumab) of which plasma samples were available before and after treatment were included retrospectively (P-CT group). AMH, FSH, and estradiol were analyzed before and after treatment, then compared to a retrospective cohort of TNBC patients treated with chemotherapy alone (cyclophosphamide/anthracycline/taxanes) (No-P group).</p><p><strong>Results: </strong>P-CT patients (N = 17) and No-P patients (N = 62) had comparable median age, BMI, smoking exposure, BRCA status, oral hormonal contraceptive use at diagnosis, and baseline AMH. Drugs used were comparable in both groups, except for carboplatin and pembrolizumab, only used in P-CT group. One year after the start of treatment, AMH fell from 1.08 to 0.01 ng/mL (p = 0.0001) and from 1.39 to 0.018 ng/mL (p < 0.0001), in the P-CT and No-P groups, respectively, without difference according to pembrolizumab exposure (p = 0.25). 9/17 P-CT patients (53%), and 21/62 No-P patients (34%), had undetectable AMH after treatment (p = 0.25). FSH and estradiol were comparable between the two groups, before and after treatment.</p><p><strong>Conclusion: </strong>No additional impact of pembrolizumab versus chemotherapy alone on AMH evolution was observed in TNBC patients < 43 years. Nevertheless, undetectable AMH 1 year after the start of treatment was common in the P-CT group. Larger studies are essential to confirm these preliminary results and assess long-term impact of pembrolizumab on ovarian reserve.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"79-86"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hormone-associated dietary patterns and premenopausal breast cancer risk.","authors":"Sable N Fest, Leslie V Farland, David R Doody, A Heather Eliassen, Bernard A Rosner, Teresa T Fung, Susan E Hankinson, Thomas W Kensler, Walter C Willett, Holly R Harris","doi":"10.1007/s10549-025-07689-4","DOIUrl":"10.1007/s10549-025-07689-4","url":null,"abstract":"<p><strong>Purpose: </strong>Circulating levels of sex steroid hormones have previously been associated with premenopausal breast cancer risk. Few studies have considered the association between dietary patterns and premenopausal hormone levels. Our objective was to derive dietary patterns associated with premenopausal hormone levels and investigate the association between pattern scores and premenopausal breast cancer risk.</p><p><strong>Methods: </strong>Using reduced rank regression among a subset of participants from the Nurses' Health Study II (NHSII) (n = 8,962), we identified dietary patterns correlated with premenopausal levels of five sex steroid hormones measured in the follicular and luteal phases. Then, in the full NHSII cohort (n = 90,341), we used Cox proportional hazards models to calculate hazard ratios (HRs) for breast cancer risk associated with each dietary pattern score.</p><p><strong>Results: </strong>Dietary patterns were identified for luteal estradiol, luteal free estradiol, follicular estrone, luteal estrone, and free testosterone. However, these patterns explained a low percent variation in individual hormone levels, ranging from 2.5-4.1%. During 24 years of follow-up, 1,956 premenopausal breast cancer cases were ascertained. Dietary patterns associated with luteal free estradiol (HR for fifth versus first quintile = 1.29; 95% CI = 1.11-1.49; P_trend < 0.01) and follicular estrone (HR for fifth versus first quintile = 1.28; 95% CI = 1.10-1.49; P_trend < 0.01) were positively associated with premenopausal breast cancer risk.</p><p><strong>Conclusion: </strong>Our findings indicate that while some dietary factors may marginally influence premenopausal hormone levels, the relation between sex steroid hormones and premenopausal breast cancer risk is likely not driven by diet. Future studies should consider other mechanisms through which diet may impact breast cancer risk, including inflammatory processes.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"23-35"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A disease registry study to prospectively observe treatment patterns and outcomes in patients with HER2-positive unresectable LA/MBC: final results of the ESTHER study.","authors":"Alistair Ring, Stephanie Sutherland, Catherine Harper-Wynne, James Owen, Thibaut Sanglier, Galina Velikova","doi":"10.1007/s10549-025-07708-4","DOIUrl":"10.1007/s10549-025-07708-4","url":null,"abstract":"<p><strong>Purpose: </strong>There are multiple contemporary systemic therapy options for patients with HER2-positive advanced breast cancer. However, there are few longitudinal data regarding what proportion of patients go on to receive later lines of therapy, real-world outcomes and the impact of brain metastases. We therefore conducted a prospective, multicentre non-interventional study to describe the anti-cancer treatment regimens used and clinical outcomes in patients with HER2-positive advanced breast cancer across multiple lines of therapy undergoing treatment in routine clinical care.</p><p><strong>Methods: </strong>Adult patients diagnosed with HER2-positive advanced breast cancer were recruited to a prospective, multicentre non-interventional study to observe treatment patterns and outcomes.</p><p><strong>Results: </strong>Three hundred and eleven patients were recruited with median age 57 years. Of those patients initiating first, second-, and third-line treatment, 72 (23.2%), 59 (41.3%), and 20 (35%), respectively had passed away without advancing on to subsequent lines of therapy. The median progression-free survival in the first line was 25.8 months and overall survival 56.7 months. Over the course of the study 107 (34.4%) of participants were diagnosed with CNS metastases. Median overall survival from diagnosis of brain metastases was 15.4 months.</p><p><strong>Conclusions: </strong>Many patients treated in routine practice may not get to benefit from contemporary second and later line treatments, where brain metastases become increasingly common. These findings have implications for selection of optimal systemic therapy sequencing in advanced HER2-positive breast cancer.</p><p><strong>Clinical trial registration: </strong>This study was approved by Nottingham Research Ethics Committee on 29th December 2014.</p><p><strong>Clinical trial registration: </strong>NCT02393924.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"113-121"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12086108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor-positive breast cancer.","authors":"Connie Lau, Krista LaBorde, Bilqees Fatima, Shahad S Alfartosy, Susan Abughosh, Rodrigo De La Torre, Erika N Brown, Meghana V Trivedi","doi":"10.1007/s10549-025-07701-x","DOIUrl":"10.1007/s10549-025-07701-x","url":null,"abstract":"<p><strong>Purpose: </strong>Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy improve survival in patients with hormone receptor-positive, HER2-negative (HR + /HER2-) breast cancer (BC). This retrospective study aimed to evaluate CDK4/6i adherence, factors associated with non-adherence, the impact of health-system specialty pharmacy on adherence, and effects of non-adherence on survival outcomes in HR + /HER2- BC patients.</p><p><strong>Methods: </strong>Data was collected from Houston Methodist Hospital System (HM) from HR + /HER2- BC patients with medication fill history utilizing electronic medical records. CDK4/6i adherence was calculated using the mean possession ratio ≥ 80%. Multivariable logistic regression model and Kaplan-Meier analysis were utilized to evaluate factors associated with non-adherence and its impact on survival, respectively.</p><p><strong>Results: </strong>A total of 121 patients were assessed and analyzed; 55% patients received abemaciclib, 40% were on palbociclib, and 4% were on ribociclib. More patients were on aromatase inhibitors and tamoxifen (79%) than fulvestrant (21%). Most of the patients were Caucasian (64%), non-Hispanic or Latino (84%), and postmenopausal (66%). Overall, 52 patients (43%) were non-adherent. Patients ≥ 65 years of age (OR: 0.304, [95% CI: 0.110-0.840], P-value: 0.022) and those of Hispanic or Latino ethnicity (OR: 0.291, [95% CI: 0.086-0.985], P-value: 0.047) were more likely to be non-adherent to CDK4/6i. Non-adherence to CDK4/6i was associated with worse overall survival and progression-free survival.</p><p><strong>Conclusion: </strong>43% patients were non-adherent to CDK4/6i. Older patients and those of Hispanic ethnicity were more likely to be non-adherent. Non-adherent patients had worse survival outcomes, highlighting the unmet need to implement interventions to improve CDK4/6i adherence in these patients.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"71-78"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival outcomes after pathologic complete response with neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy: a retrospective national database study.","authors":"Tori C Nierenberg, Samantha M Thomas, Ian Halliday, Astrid Botty van den Bruele, Akiko Chiba, Kendra J Modell Parrish, Hannah E Woriax, Maggie L DiNome, Kelly E Westbrook, Jennifer K Plichta","doi":"10.1007/s10549-025-07717-3","DOIUrl":"10.1007/s10549-025-07717-3","url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant therapies can result in pathologic complete response (pCR) in patients with breast cancer, which can be predictive of long-term outcomes. Patients with estrogen receptor positive (ER +) tumors may receive either neoadjuvant chemotherapy (NAC) or neoadjuvant endocrine therapy (NET). We sought to compare survival outcomes in those with non-metastatic ER + breast cancer who received NET or NAC and achieved pCR.</p><p><strong>Methods: </strong>All patients diagnosed with ER + /HER2- stage I-III breast cancer, who received neoadjuvant systemic therapy followed by surgery, and achieved pCR, were selected from the National Cancer Database (NCDB, 2010-2021). The Kaplan-Meier method was used to estimate overall survival (OS), and log-rank tests were used to test for differences in OS. Cox Proportional Hazards models were used to estimate the association of NAC vs NET with OS, after adjustment for covariates.</p><p><strong>Results: </strong>3313 patients met eligibility criteria: 3148 received NAC and 165 NET. The median follow-up for the entire cohort was 82 months (95% CI 80.4-83.1). Patients who received NAC were significantly younger (median age: NAC 49y vs NET 64y; p < 0.001), more likely to have a comorbidity score of 0 (NAC 89.3% vs NET 81.2%, p = 0.004), and more likely to have private insurance (NAC 68.9% vs NET 44.2%, p < 0.001). There were no significant differences between the NAC and NET patients based on race and ethnicity, income, education, or community type (all p > 0.05). The NAC treated patients were more likely to have larger tumors [median tumor size (IQR): NAC 3 cm (2.0-4.3) vs NET 1.3 cm (0.7-2.8); p < 0.001)], ductal histology (NAC 92.6% vs 81.2%, p < 0.001), and grade 3 tumors (NAC 70.2% vs 10.3%, p < 0.001). In the unadjusted Kaplan-Meier analysis, there was no significant difference in OS between NAC vs NET [5-year OS: NAC 0.935 vs NET 0.916; p = 0.08]. After adjustment for demographics, disease characteristics, and treatments, there remained no association between OS and study group (NAC vs NET; p = 0.63).</p><p><strong>Conclusions: </strong>Patients with ER + /HER2- early-stage breast cancer who achieved pCR had similar OS, regardless of whether they received NAC or NET. As such, pCR appears to have similar prognostic value irrespective of the type of systemic therapy used to obtain this favorable outcome.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"161-172"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Population-based analysis of breast cancer incidence and mortality: overall and age-specific temporal trends over 40-year period in Girona, Spain.","authors":"Arantza Sanvisens, Anna Vidal-Vila, Montse Puigdemont, Gemma Viñas, Ariadna Roqué-Lloveras, Sonia Del Barco, Ferran Pérez-Bueno, Jan Trallero, Rafael Marcos-Gragera, Gemma Renart","doi":"10.1007/s10549-025-07704-8","DOIUrl":"10.1007/s10549-025-07704-8","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer (BC) incidence and mortality in women have changed over time. This study aims to analyze population-level incidence and mortality trends over 40 years of observation.</p><p><strong>Methods: </strong>Population-based study of BC conducted by Girona Cancer Registry covering the period 1980-2019. Age-standardized incidence and mortality rates were calculated. Poisson change-point regression models were used to analyze trends, calculating the annual percentage change (APC).</p><p><strong>Results: </strong>A total of 12,283 diagnoses of invasive BC between 1980 and 2019. The overall age-standardized incidence rate was 109.9 (95% confidence intervals (CI) 104.4; 115.4) cases per 100,000 women-years. Trend analyses showed a statistically significant incidence increase of 4.2% per year from 1980 to 1994 (95%CI 3.3; 5.1), and a stabilization between 1994 and 2019, with an APC of 0.28% (95%CI - 0.04; 0.56). These trends were similar for the age groups 0-49 years and 50-69 years. In women over 69 years of age, an increase in incidence of 4.4% (95%CI 2.8; 6.0) per year was observed between 1980 and 1995 followed by a non-statistically significant decrease of - 0.35% (95%CI - 0.86; 0.15) between 1995 and 2019. The overall age-standardized mortality rate was 30.3 (95%CI 29.3; 31.3) cases per 100,000 women-years. Mortality rate trends showed a statistically significant decrease of - 1.87% (95%CI - 2.38; - 1.37) per year since 1992.</p><p><strong>Conclusion: </strong>There has been a stabilization in the incidence of BC and a gradual decline in BC mortality in women. The introduction of mammography in the mid-1990s, alongside early detection and treatment due to screening programs may play a significant role in the reduction of BC burden in women of all ages.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"97-105"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12086112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the possibility of omitting axillary surgery in patients with clinical node-positive breast cancer achieving ypT0 after neoadjuvant chemotherapy.","authors":"Hideo Shigematsu, Momoko Takaya, Kanako Suzuki, Mutsumi Fujimoto, Haruka Ikejiri, Ai Amioka, Emiko Hiraoka, Shinsuke Sasada, Koji Arihiro, Morihito Okada","doi":"10.1007/s10549-025-07697-4","DOIUrl":"10.1007/s10549-025-07697-4","url":null,"abstract":"<p><strong>Purpose: </strong>Axillary staging is commonly performed in patients with clinically node-positive (cN+) breast cancer undergoing neoadjuvant chemotherapy (NACT), regardless of pathological complete response (pCR). Recent evidence has suggested that ypT0 correlates with ypN0 and favorable prognosis, potentially supporting the omission of axillary staging in such cases. This study aimed to evaluate ypT0 as a predictive factor for ypN status and its prognostic significance in cN+ breast cancer treated with NACT.</p><p><strong>Methods: </strong>This retrospective study included 302 patients with cN+ breast cancer treated with NACT at Hiroshima University Hospital between 2006 and 2022. Patients were categorized into non-pCR, ypTis, or ypT0 based on ypT status. Associations between breast pCR, ypN status, recurrence-free survival (RFS), and overall survival (OS) were analyzed.</p><p><strong>Results: </strong>Among 302 patients (non-pCR, 74.2%; ypTis, 8.9%; ypT0, 16.9%), the ypN+ rates were 63.3%, 15.2%, and 3.9%, respectively. Logistic regression revealed significant associations among ypT0, ypTis, and ypN0. The five-year RFS and OS rates were 78.6% and 85.2% (non-pCR), 83.8% and 95.5% (ypTis), and 98.0% and 100.0% (ypT0), respectively. Cox regression identified ypT0, but not ypTis, as a significant prognostic factor for both RFS and OS.</p><p><strong>Conclusion: </strong>ypT0 status was associated with a low risk of ypN+ and favorable clinical outcomes in cN+ breast cancer, suggesting the potential feasibility of omitting axillary surgery in select patients.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"47-56"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12086105/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}